- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03406611
Pegtibatinase como terapia enzimática para pacientes com homocistinúria causada por deficiência de cistationina beta-sintase (COMPOSE)
Um estudo duplo-cego, randomizado, controlado por placebo, de fase 1/2 para avaliar a segurança, tolerabilidade, farmacocinética, farmacodinâmica e efeitos nos resultados clínicos da pegtibatinase (TVT-058), administrada por via subcutânea em pacientes com homocistinúria deficiente em cistationina beta-sintase (COMPOR)
A homocistinúria causada pela Deficiência de Cistationina Beta-Sintase (CBS) é uma rara condição metabólica autossômica recessiva caracterizada por um excesso de homocisteína (Hcy) no plasma, tecidos e urina. É devido à atividade reduzida ou ausente da enzima CBS e também é conhecida como homocistinúria clássica. Os sintomas associados à homocistinúria variam em gravidade e tempo de início entre os pacientes. Alguns indivíduos afetados podem apresentar sinais leves do distúrbio; outros podem ter envolvimento multissistêmico, incluindo complicações potencialmente fatais. A homocistinúria pode afetar muitos sistemas de órgãos diferentes do corpo; os quatro mais comumente envolvidos são os olhos, o sistema nervoso central, o esqueleto e o sistema vascular.
As abordagens atuais para o tratamento de pacientes com homocistinúria incluem uma dieta altamente restritiva e o uso de suplementos dietéticos. A adesão ao longo da vida a esta dieta é pobre. A pegtibatinase (TVT-058) representa uma nova abordagem terapêutica que incorpora o uso de uma versão modificada da enzima CBS humana nativa (hCBS). O objetivo do tratamento é introduzir a enzima CBS na circulação, resultando em níveis reduzidos de Hcy, aumento dos níveis de cistationina (Cth) e cisteína (Cys).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Primary Objective - Cohorts 1-6
Researchers are performing this study to learn if pegtibatinase is safe and tolerable (how it makes participants feel).
Researchers will use medical examination, blood tests, and urine tests to measure side effects (unwanted health problems that may or may not be related to the study treatment), changes in laboratory tests and in the electrical activity of the heart (as measured by electrocardiogram or "ECG"), and if the body makes antibodies to fight against pegtibatinase. Antibodies are proteins that the body makes that may stop pegtibatinase from working or may cause side effects.
Secondary Objectives - Cohorts 1-6
Researchers also want to learn about:
- What are the levels of pegtibatinase in the body after single and repeated doses?
- How does pegtibatinase affect levels of certain substances that are produced when the body breaks down and creates homocysteine?
- What are the effects of pegtibatinase on the eyes, bones, mental health, and cognitive function? Researchers will use blood tests, physical examinations, and questionnaires to answer these questions.
Cohort 7 Objectives
Group 7 is open to children aged 5 to 11 years old (or "pediatric participants") who meet the requirements for the study.
Researchers are performing this part of the study with Group 7 to learn if pegtibatinase is safe and tolerable (how it makes participants feel) and if it increases antibody levels when it is given to children with HCU.
Researchers will use blood tests and physical examinations to measure side effects that happen during the study, changes in laboratory tests, electrical activity of the heart, antibody levels, vital signs, and the number of pediatric participants that have too high or too low levels of methionine. Researchers will use questionnaires to measure the number of pediatric participants that need more protein in their diet.
Researchers are performing this part of the study with Group 7 because they also want to learn about:
- What are the levels of pegtibatinase in the pediatric participant's body after single and repeated doses?
- How does pegtibatinase affect levels of total homocysteine and methionine in the pediatric participant's body? Researchers will use blood tests to answer these questions.
Study Population and Treatments
This study will include children and adults from 5 to 65 years old with HCU. Participants in Groups 1 to 6 were aged 12 to 65 years old, and Group 7 participants will be aged 5 to 11 years old. Participants in the study will take their standard of care treatment.
Groups 1 to 6 have completed this study already. For these groups, 24 participants aged 12 to 65 years old who met the requirements of the study were split into 1 of the 6 groups. For each group, 3 participants were chosen to take pegtibatinase for every 1 participant chosen to take an injection that does not have any medicine in it (or "placebo"). Participants were assigned to pegtibatinase or placebo by chance, like the flip of a coin. This is called "randomization". Neither the researchers nor the participants knew which treatment they were getting until the study was completed. This is known as a "double-blind" approach.
Group 7 is open and will be conducted globally. It will include 10 to 15 pediatric participants aged 5 to 11 years old who meet the requirements of the study. All participants in this group will receive pegtibatinase. All participants will know that this is the treatment that they receive. This is called an "open label" approach. The treatment period will be separated into 3 parts: Part A, Part B, and Part C. Each part will test a different dose of pegtibatinase. After each part, pediatric participants who meet specific requirements will move to the next part. If the pediatric participants do not meet specific requirements to move to the next part, they will have the option to join the ENSEMBLE study (NCT06431893) and continue taking that same dose.
Pegtibatinase or placebo will be given as an injection under the skin (or "subcutaneous injection"). Doses for each group are shown below.
- Group 1: 0.33 mg/kg pegtibatinase or placebo 1 time a week.
- Group 2: 0.66 mg/kg pegtibatinase or placebo 1 time a week.
- Group 3: 1.0 mg/kg pegtibatinase or placebo 1 time a week.
- Group 4: 1.0 mg/kg pegtibatinase or placebo 2 times a week.
- Group 5: 1.5 mg/kg pegtibatinase or placebo 2 times a week.
- Group 6: 2.5 mg/kg pegtibatinase or placebo 2 times a week.
- Group 7:
- Part A: 1.0 mg/kg pegtibatinase 2 times a week for 8 weeks;
- Part B: 1.5 mg/kg pegtibatinase 2 times a week for 8 weeks;
- Part C: 2.5 mg/kg pegtibatinase 2 times a week for 4 weeks.
Study Duration and Visits
Participants in Groups 1 to 6 were in the study for up to 158 weeks, including the screening period of up to 8 weeks, a double-blind treatment period of up to 12 weeks, and an extension period of up to 138 weeks. A continuation study called ENSEMBLE was available to participants. Participants were offered to join the ENSEMBLE study before they finished the extension period of the COMPOSE study.
Pediatric participants in Group 7 may be in the study for up to 42 weeks, including the screening period of up to 10 weeks, open-label treatment period of up to 20 weeks, and up to 12 weeks of additional treatment at the same dose if the ENSEMBLE study is not yet open.
If participants in Group 7 meet all the requirements of the study, they will have up to 53 visits to a study center or at home. If the ENSEMBLE study is not yet open at their site, they can have up to 23 more visits to continue treatment.
These visits can include:
- Blood and urine tests
- Physical examinations
- Questionnaires
- Injections
- Questions about how they are feeling or any problems they are having
Safety / Adverse Events
Researchers will keep track of any medical problems that a participant has during a study (or "adverse event"). All participants in this study will have regular laboratory tests, health checkups, and site visits to watch for health risks and measure safety.
Benefit-Risk Conclusion Researchers have worked to reduce risks to participants in this study. They believe the risks of taking pegtibatinase in this study are justified by the potential benefits that they think pegtibatinase may have for people with HCU.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Travere Call Center
- Número de telefone: 1-877-659-5518
- E-mail: medinfo@travere.com
Locais de estudo
-
-
-
Doha, Catar
- Ainda não está recrutando
- Sidra Medicine
-
-
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Concluído
- Travere Investigational Site
-
-
Florida
-
Miami, Florida, Estados Unidos, 33136
- Concluído
- Travere Investigational Site
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Ainda não está recrutando
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Concluído
- Travere Investigational Site
-
-
Maine
-
Portland, Maine, Estados Unidos, 04102
- Concluído
- Travere Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Concluído
- Travere Investigational Site
-
-
New York
-
New York, New York, Estados Unidos, 10029
- Ainda não está recrutando
- The Mount Sinai Hospital
-
New York, New York, Estados Unidos, 10029
- Concluído
- Travere Investigational Site
-
-
North Carolina
-
Morrisville, North Carolina, Estados Unidos, 27560
- Recrutamento
- Science 37 - Virtual Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Concluído
- Travere Investigational Site
-
-
-
-
-
Paris, França, 75015
- Ainda não está recrutando
- Hospital Necker-Enfants Malades, Neurologie Pediatrique
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Descrição
Critério de inclusão:
- Diagnóstico confirmado de homocistinúria com base na confirmação genética e plasma tHcy ≥50 micromoles e documentação do nível anterior de tHcy ≥80 micromoles
- Disposto e capaz de fornecer consentimento informado por escrito e assinado e de cumprir todos os procedimentos relacionados ao estudo.
- Indivíduos nascidos biologicamente como mulheres com potencial para engravidar devem ter um teste de gravidez negativo na triagem e estar dispostos a fazer testes de gravidez adicionais durante o estudo. Indivíduos nascidos biologicamente como homens que se identificam como mulheres e não têm potencial para engravidar não são obrigados a se submeter a testes de gravidez
- Sujeitos sexualmente ativos que têm potencial para engravidar ou aqueles que têm parceiros com potencial para engravidar devem estar dispostos a usar métodos contraceptivos aceitáveis durante o estudo e por 4 semanas após o final do estudo
- Disposto a manter uma dieta estável sem modificações significativas durante o estudo e completar um diário alimentar diário.
Critério de exclusão:
- Exposição anterior à pegtibatinase e/ou participação anterior em um ensaio clínico que incluiu a administração de pegtibatinase
- Uso de qualquer produto experimental ou dispositivo médico experimental dentro de 30 dias antes da triagem ou durante o estudo
- Uso ou uso planejado de qualquer medicamento injetável contendo PEG (exceto vacinas pegtibatinase ou COVID-19), incluindo injeção de medroxiprogesterona (por exemplo, Depo-Provera), dentro de 3 meses antes da triagem e durante a participação no estudo
- Hipersensibilidade conhecida ao produto contendo PEG ou a qualquer componente da pegtibatinase
- Um teste positivo para anticorpo do HIV, antígeno de superfície da hepatite B ou anticorpo da hepatite C
- Uma história de transplante de órgãos, terapia imunossupressora crônica ou abuso de substâncias
- Grávida ou amamentando na triagem ou planejando engravidar (própria ou parceira) ou amamentar a qualquer momento durante o estudo
- Doença ou condição concomitante ou cirurgia de grande porte planejada que interferiria na participação no estudo ou na segurança na opinião do investigador.
- Qualquer condição que, na visão do investigador, coloque o sujeito em alto risco de má adesão ao tratamento ou de não concluir o estudo
- Grande cirurgia planejada durante o período do estudo
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Pegtibatinase (Cohort 1-6)
Double-Blind Treatment Cohorts (≥12 to ≤65 years)
|
Pegtibatinase solução estéril para injeção subcutânea
Outros nomes:
|
|
Comparador de Placebo: Placebo (Cohort 1-6)
Double-Blind Treatment Cohorts (≥12 to ≤65 years)
|
Solução salina normal para injeção subcutânea
|
|
Experimental: Pegtibatinase (Cohort 7)
Pediatric Open-label Treatment Cohort (≥5 to <12 years)
|
Pegtibatinase solução estéril para injeção subcutânea
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of AEs
Prazo: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Incidence of AEs (by type, severity and relationship to study drug)
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Anti-pegtibatinase antibodies
Prazo: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Presence and levels of anti-pegtibatinase antibodies in plasma as measured by antibody titers
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Anti-PEG antibodies
Prazo: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Presence and levels of anti-PEG antibodies in plasma as measured by antibody titers
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Incidence of hypermethioninemia (Cohort 7 only)
Prazo: First dose through End of Treatment (up to Week 32)
|
The number and percentage of participants who develop hypermethioninemia during treatment, based on plasma methionine concentrations exceeding the protocol-defined threshold.
Participants meeting the protocol-defined threshold may undergo dietary management or study treatment modifications, as appropriate.
|
First dose through End of Treatment (up to Week 32)
|
|
Incidence of hypomethioninemia (Cohort 7 only)
Prazo: First dose through End of Treatment (up to Week 32)
|
The number and percentage of participants who develop hypomethioninemia during treatment, based on plasma methionine concentrations below the protocol-defined threshold.
Participants meeting the protocol-defined threshold may receive dietary protein supplementation or study treatment modifications, as appropriate.
|
First dose through End of Treatment (up to Week 32)
|
|
The proportion of participants requiring dietary protein rescue (Cohort 7 only)
Prazo: First dose through End of Treatment (up to Week 32)
|
The proportion of participants who require initiation of dietary protein supplementation during study treatment to manage protocol-defined low plasma methionine concentrations.
|
First dose through End of Treatment (up to Week 32)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Changes in pegtibatinase levels
Prazo: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Changes in pegtibatinase levels following single and repeat administration at specified timepoints
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Changes in Met cycle metabolites levels - tHcy
Prazo: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
Changes in total homocysteine levels in micromoles
|
• Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
|
|
Changes in Met cycle metabolites levels - total Cys (Cohorts 1-6 Only)
Prazo: Through double-blind study completion, approximately 10 months per patient
|
Changes in total cysteine levels in micromoles
|
Through double-blind study completion, approximately 10 months per patient
|
|
Changes in Met cycle metabolites levels - Me (Cohorts 1-6 Only)
Prazo: Through double-blind study completion, approximately 10 months per patient
|
Changes in methionine levels in micromoles
|
Through double-blind study completion, approximately 10 months per patient
|
|
Changes in Met cycle metabolites levels - Cth (Cohorts 1-6 Only)
Prazo: Through double-blind study completion, approximately 10 months per patient
|
Changes in cystathionine levels in micromoles
|
Through double-blind study completion, approximately 10 months per patient
|
|
Changes in Met cycle metabolites levels - Phe (Cohorts 1-6 Only)
Prazo: Through double-blind study completion, approximately 10 months per patient
|
Changes in phenylalanine levels in micromoles
|
Through double-blind study completion, approximately 10 months per patient
|
|
Descriptive ophthalmology examination findings (Cohorts 1-6 Only)
Prazo: Through double-blind study completion, approximately 10 months per patient
|
Comprehensive ophthalmological examination (for each eye: visual acuity [myopia, hyperopia, exotropia], slit lamp examination [ectopic lentis, cataracts, corneal abrasion, and uveitis], retinal examination [retinal degeneration, retinal detachment, retinitis pigmentosa, uveitis)]).
Assessment of presence and severity of findings.
|
Through double-blind study completion, approximately 10 months per patient
|
|
Bone densitometry using dual-energy X-ray absorptionmetry (DEXA) scans (Cohorts 1-6 Only)
Prazo: Through double-blind study completion, approximately 10 months per patient
|
Through double-blind study completion, approximately 10 months per patient
|
|
|
Cognitive assessments using the National Institutes of Health Toolbox Cognition Battery score (Cohorts 1-6 Only)
Prazo: Through double-blind study completion, approximately 10 months per patient
|
Through double-blind study completion, approximately 10 months per patient
|
|
|
Patient Reported Outcome (PRO): Quality of Life in Neurological Disorders [Neuro-QoL] (Cohorts 1-6 Only)
Prazo: Through double-blind study completion, approximately 10 months per patient
|
The Quality of Life in Neurological Disorders [Neuro-QoL] includes Anxiety Short Form, Depression Short Form, Satisfaction with Social Roles Short Form, Cognition Function Short Form for 18+ years of age; Anxiety Short Form, Depression Short Form, Social Relations - Interaction with Peers Short Form, and Cognitive Function Short Form for Ages 12 to 17 years old
|
Through double-blind study completion, approximately 10 months per patient
|
|
Patient Reported Outcome (PRO): Quality of Life by 36-Item Short Form Survey [SF-36] (Cohorts 1-6 Only)
Prazo: Through double-blind study completion, approximately 10 months per patient
|
Through double-blind study completion, approximately 10 months per patient
|
|
|
Patient Reported Outcome (PRO): Quality of Life by EuroQol 5-Dimentional Instrument [EQ 5D] (Cohorts 1-6 Only)
Prazo: Through double-blind study completion, approximately 10 months per patient
|
Through double-blind study completion, approximately 10 months per patient
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Michael Imperiale, MD, Travere Therapeutics, Inc.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Metabolismo, Erros Inatos
- Doenças Genéticas, Congênitas
- Doenças Metabólicas
- Doenças do Tecido Conjuntivo
- Doenças Cerebrais Metabólicas Inatas
- Doenças Cerebrais Metabólicas
- Metabolismo de Aminoácidos, Erros Inatos
- Hiper-homocisteinemia
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Doenças Nutricionais e Metabólicas
- Doenças da Pele e do Tecido Conjuntivo
- Homocistinúria
Outros números de identificação do estudo
- CBS-HCY-CT-01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .